CURA healthcare concern is extremely happy for acquiring Tuscano because it has an excellent team of R&D engineers with rich experience in hardware and software.
Pharmaceutical Company Pfizer To Shut Down its' Navi Mumbai Plant From September
There has been zero production from this plant since 2013. So the closure will not affect availability of medicines in the market.
There has been zero production from this plant since 2013. So the closure will not affect availability of medicines in the market.
"Tuscano is an apt for CURA Healthcare. Tuscano is one of the few Indian Research and Development Labs with ISO 13485 certification. Tuscano brings an excellent team of R&D engineers with rich experience in hardware and software," said M. Balasubramaniam, CEO, CURA Healthcare.
"We are happy to merge with CURA. The company has presence across medical technology segments. This sector is still at a very nascent stage and majority dominated by imports,” said Kannan Neelakanta, MD, Tuscano Equipments.
Godrej Ventures Into Vaccine Protection Sector With Sure Chill - a Britain-based Company
The company has patented the use of refrigeration that does not need constant power to refrigerate. It guarantees maintenance at a temperature of 4 degrees Celsius.
The company has patented the use of refrigeration that does not need constant power to refrigerate. It guarantees maintenance at a temperature of 4 degrees Celsius.
Indian Pharmaceutical Company Recalls Anti-seizure and Hypertension Drugs from US Market
Hyderabad-based Dr Reddy’s Laboratories recalled the drugs as the tablets failed dissolution test and some are close to expiry date.
Hyderabad-based Dr Reddy’s Laboratories recalled the drugs as the tablets failed dissolution test and some are close to expiry date.
Ranbaxy Gets the Nod to Commence Distribution of Its Anti-malarial Drug in 7 African Countries
The Indian multinational pharmaceutical company, Ranbaxy Laboratories has received regulatory nod to launch its indigenously developed anti-malarial drug, Synriam, in seven African countries.
The Indian multinational pharmaceutical company, Ranbaxy Laboratories has received regulatory nod to launch its indigenously developed anti-malarial drug, Synriam, in seven African countries.
